A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

Original title: “FDA ‘reset’ continues with new plan for reviewing rare disease drugs”

Following several recent initiatives, the FDA's newest rare disease framework sets out to standardize the agency's approach to scientific evidence and bring rare disease therapies to patients faster.

Original title: “FDA's latest rare disease framework seeks to prioritize consistency in flexibility”

The Food and Drug Administration ... therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement ... The Food and Drug Administration on Wednesday said it plans to “reimagine” the way it regulates therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement through post-marketing requirements, the agency said in a white paper. A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said. But rare disease development is even harder; there are fewer patients available for research and less knowledge about both the condition and potential biomarkers that can serve as endpoints for a trial. That has often left regulators in a quandary as they try to weigh the routine demand for clear evidence of safety and efficacy against the need for new treatments for devastating conditions. Some 30 million Americans live with a rare disease, according to the FDA. But as of last year, only about 5% of recognized rare conditions had an approved treatment.

Original title: “FDA ‘reset’ continues with new plan for reviewing rare disease drugs | Healthcare Dive”

The Food and Drug Administration ... therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement ... The Food and Drug Administration on Wednesday said it plans to “reimagine” the way it regulates therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement through post-marketing requirements, the agency said in a white paper. A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said. But rare disease development is even harder; there are fewer patients available for research and less knowledge about both the condition and potential biomarkers that can serve as endpoints for a trial. That has often left regulators in a quandary as they try to weigh the routine demand for clear evidence of safety and efficacy against the need for new treatments for devastating conditions. Some 30 million Americans live with a rare disease, according to the FDA. But as of last year, only about 5% of recognized rare conditions had an approved treatment.

Original title: “FDA ‘reset’ continues with new plan for reviewing rare disease drugs | Healthcare Dive”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 10810: National Patient Safety Board Act of 2026”

The Food and Drug Administration (FDA or the Agency) is announcing the issuance of four Emergency Use Authorizations (EUA or Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for new animal products. FDA has issued one EUA for an animal product as requested by Elanco US Inc. for application on or around wounds for the prevention of infestations caused by New World screwworm (Cochliomyia hominivorax; NWS) larvae (myiasis) in sheep, cattle, goats, swine, camelids, and the fo

Original title: “Authorization of Emergency Use for Four Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability”

The Centers for Disease Control and Prevention (CDC), a component of the Department of Health and Human Services (HHS), announces it is issuing an Order under Sections 362 and 365 of the Public Health Service Act, and associated implementing regulations, continuing the suspension of the right to introduce certain persons from countries where an outbreak of a quarantinable communicable disease exists. This Order was issued on October 11 and shall remain in effect through 4:59 p.m. Eastern Dayligh

Original title: “Order Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Exists”

The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Tobacco Products Scientific Advisory Committee (TPSAC), in the Center for Tobacco Products. FDA seeks to include the views of qualified individuals on its advisory committees and therefore encourages nominations of appropriately qualified candidates. Specifically, TPSAC is seeking to fill 2 voting member vacancies with physicians, dentists, scientists, or health care professionals practicing in the areas

Original title: “Request for Nominations for Voting Members on a Public Advisory Committee; Tobacco Products Scientific Advisory Committee (TPSAC)”

The FDA’s Rare Disease Framework aims to speed rare disease drug development using flexible evidence standards. Read more here. Oct 14, 2026, 1:16 PM ETIntellia Therapeutics, Inc. (NTLA) Stock, BEAM Stock, RARE Stock, SRPT Stock, BBIO Stock, IONS Stock, RCKT Stock, KRYS StockBy: Jonathan Block, SA News Editor · The US FDA has launched a Rare Disease Framework Initiative that is designed to reflect "the realities of rare disease drug development by considering the nuances of each disease, patient needs, product type and the evidence that can be realistically generated in small

Original title: “FDA unveils rare disease initiative to enhance therapy development | Seeking Alpha”

Today represents an extraordinary inflection point for our community.   This morning, the FDA announced it would undertake a new initiative to take a fresh look at how it approaches rare […]

Original title: “FDA Introduces a New Framework for Rare Disease Review”

The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.

Original title: “FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development”

The Food and Drug Administration (FDA) is announcing the renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cellular, Tissue, and Gene Therapies Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 28, 2028, expiration date.

Original title: “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal”

The Department of Health and Human Services, Administration for Children and Families proposes to further amend the Native American Programs Act regulations to streamline the part.

Original title: “Further Reducing Bureaucracy and Burden From the Administration for Native Americans”

The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium propionate as a source of chromium in food for laying hens and breeder chickens. This action is in response to a food additive petition filed by Kemin Industries, Inc.

Original title: “Food Additives Permitted in Feed and Drinking Water of Animals; Chromium Propionate”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Performance Monitoring of CDC's Comprehensive Suicide Prevention Program. This progr

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

HRSA published a document in the Federal Register on September 24, 2026, concerning performance period extensions for health centers scheduled to compete for a January, February, or March FY 2027 Service Area Competition. The document did not include one service area that was not eligible for a performance period extension at the time of publication but has since become eligible.

Original title: “Health Center Program Performance Period Extensions; Correction”

The Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the Office of the Director (OD), National Institutes of Health (NIH) is seeking public comment regarding its proposal to establish the Office of the NIH Chief Artificial Intelligence Officer (OCAIO) within DPCPSI and move the Office of Dietary Supplements (ODS) under the Office of Nutrition Research (ONR) within DPCPSI in OD, NIH.

Original title: “Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director Notice of Proposed Reorganization”

Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”

In compliance with the Paperwork Reduction Act (PRA) of 1995, which requires a 60-day public comment period on proposed information collection projects, the Indian Health Service (IHS) invites the public to take this opportunity to comment on the information collection titled, "Purchased/Referred Care (PRC) Proof of Residency" The purpose of this notice is to announce our intent to seek reinstatement of the previously approved information collection by the Office of Management and Budget (OMB),

Original title: “Request for Public Comment: 60-Day Notice for Proposed Information Collection: Indian Health Service Purchased/Referred Care Proof of Residency”